| Non-Small Cell Lung Carcinoma
Abraxane vs Enhertu
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Abraxane vs Enhertu with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEnhertu has a higher rate of injection site reactions vs Abraxane based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Enhertu but not Abraxane, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Abraxane
Enhertu
At A Glance
IV infusion
Weekly to every 3 weeks
Microtubule inhibitor
IV infusion
Every 3 weeks
HER2-directed antibody-drug conjugate with topoisomerase I inhibitor
Indications
- Carcinoma breast stage IV
- Non-Small Cell Lung Carcinoma
- Adenocarcinoma of pancreas
- Breast Carcinoma
- Non-Small Cell Lung Carcinoma
- Gastric Adenocarcinoma
Dosing
Carcinoma breast stage IV 260 mg/m2 IV over 30 minutes every 3 weeks.
Non-Small Cell Lung Carcinoma 100 mg/m2 IV over 30 minutes on Days 1, 8, and 15 of each 21-day cycle; administer carboplatin on Day 1 of each 21-day cycle immediately after ABRAXANE.
Adenocarcinoma of pancreas 125 mg/m2 IV over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle; administer gemcitabine on Days 1, 8, and 15 of each 28-day cycle immediately after ABRAXANE.
Breast Carcinoma (HER2-positive, HER2-low, or HER2-ultralow) 5.4 mg/kg IV infusion every 3 weeks until disease progression or unacceptable toxicity
Breast Carcinoma (HER2-positive, first-line with pertuzumab) Cycle 1 Day 1: 5.4 mg/kg IV followed by pertuzumab 840 mg; subsequent cycles: 5.4 mg/kg IV followed by pertuzumab 420 mg every 3 weeks
Non-Small Cell Lung Carcinoma (HER2-mutant) 5.4 mg/kg IV infusion every 3 weeks until disease progression or unacceptable toxicity
Gastric Adenocarcinoma (HER2-positive) 6.4 mg/kg IV infusion every 3 weeks until disease progression or unacceptable toxicity
Contraindications
- Baseline neutrophil count below 1500 cells/mm3
- History of severe hypersensitivity reaction to ABRAXANE
—
Adverse Reactions
Most common (>=20%) Alopecia, neutropenia, sensory/peripheral neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, diarrhea, thrombocytopenia, peripheral edema, pyrexia, vomiting, decreased appetite, rash, dehydration
Serious Anemia, pneumonia, pyrexia, dehydration, vomiting
Postmarketing Severe hypersensitivity reactions, congestive heart failure, left ventricular dysfunction, atrioventricular block, pneumonitis, interstitial pneumonia, pulmonary embolism, cranial nerve palsies, vocal cord paresis, autonomic neuropathy, cystoid macular edema, hepatic necrosis, intestinal obstruction, intestinal perforation, pancreatitis, ischemic colitis, tumor lysis syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis
Most common (>=20%) Decreased white blood cell count, nausea, decreased hemoglobin, decreased neutrophil count, decreased lymphocyte count, fatigue, decreased platelet count, increased aspartate aminotransferase, increased alanine aminotransferase, increased blood alkaline phosphatase, vomiting, alopecia, decreased blood potassium, constipation, musculoskeletal pain, diarrhea, decreased appetite
Serious Interstitial lung disease, pneumonitis, pneumonia, febrile neutropenia, vomiting, nausea, hypokalemia, pulmonary embolism, sepsis
Pharmacology
ABRAXANE is a microtubule inhibitor that promotes assembly and stabilization of microtubules from tubulin dimers, inhibiting the normal dynamic reorganization of the microtubule network essential for vital interphase and mitotic cellular functions.
Fam-trastuzumab deruxtecan-nxki is a HER2-directed antibody-drug conjugate consisting of a humanized anti-HER2 IgG1 antibody linked to a topoisomerase I inhibitor (DXd). After binding to HER2 on tumor cells, the drug undergoes internalization and lysosomal cleavage, releasing the membrane-permeable DXd that causes DNA damage and apoptotic cell death.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Abraxane
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
Enhertu
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Abraxane
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Enhertu
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Abraxane
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Enhertu
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Abraxane.
No savings programs available for Enhertu.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AbraxaneView full Abraxane profile
EnhertuView full Enhertu profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.